Cochrane for Clinicians
Putting Evidence into Practice
Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder
Am Fam Physician. 2015 Feb 1;91(3):165-166.
Author disclosure: No relevant financial affiliations.
Is buprenorphine maintenance treatment effective in the management of opioid use disorder?
At dosages greater than 2 mg per day, buprenorphine maintains treatment retention better than placebo. (Strength of Recommendation: A, based on consistent, good-quality patient-oriented evidence.) At 16 mg or more per day, buprenorphine was found to reduce illicit substance use compared with placebo as monitored by urinalysis. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
When flexible dosing (doses adjusted based on patient symptoms) is used, the effectiveness of buprenorphine is comparable to that of methadone in suppressing opioid use. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.) When fixed dosing (a set dose is given) of 7 mg or more is used, buprenorphine and methadone are equally effective as measured by retention in treatment and suppression of illicit opioid use. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
The Diagnostic and Statistical Manual of Mental Disorders, 5th ed., combines “opioid abuse” and “opioid dependence” into the new diagnosis “opioid use disorder,” categorized as mild, moderate, or severe based on the number of positive symptoms.1 Pharmacologic treatment options for opioid use disorder include methadone and buprenorphine. Buprenorphine is usually prescribed as a combination formulation that includes the pharmacologically inactive naloxone, except in pregnancy when it is recommended that buprenorphine be used alone. Both methadone and buprenorphine are intended to be administered in conjunction with psychosocial treatment, with the goal of eliminating withdrawal symptoms and maintaining the patient on a documented and regulated dosage. Because buprenorphine is a partial agonist, there is a ceiling effect to the level of respiratory depression or sedation it can cause, reducing the risk of overdose. Buprenorphine may be prescribed by primary care physicians who complete eight hours of training and receive a waiver from the Drug Enforcement Administration.
This analysis included 31 randomized controlled trials (5,430 participants) comparing buprenorphine maintenance with placebo or methadone maintenance. Primary outcomes were retention in treatment and continued use of opioids as measured by self-report or urinalysis. Various dosing regimens were used. All dosages of buprenorphine were superior to placebo in treatment retention: 7 to 15 mg per day (relative risk [RR] = 1.74; 95% confidence interval [CI], 1.06 to 2.87), and 16 mg or more per day (RR = 1.82; 95% CI, 1.15 to 2.90). Thus, given a baseline retention rate of 40% in those receiving placebo, the retention rate would increase to approximately 70% in those receiving 7 to 15 mg of buprenorphine and to 73% in those using at least 16 mg of buprenorphine daily. Only high-dosage buprenorphine (at least 16 mg per day) was effective—and then, only mildly—in suppressing illicit opioid use when monitored by urinalysis (standardized mean difference [SMD] = −1.17; 95% CI, −1.85 to −0.49).
In studies comparing buprenorphine maintenance with methadone maintenance, flexible dosing and fixed dosing were evaluated. In analyses of flexible dosing, buprenorphine was less effective than methadone in treatment retention (RR = 0.83; 95% CI, 0.72 to 0.95), but there was no difference between groups in suppression of opioid use when monitored by urinalysis (SMD = −0.11; 95% CI, −0.23 to 0.02). However, when fixed dosing was studied, medium (7 to 15 mg) and high (16 mg or more) doses of buprenorphine were found to be equivalent to medium (40 to 85 mg) and high (85 mg or more) fixed doses of methadone in terms of retention and suppression of illicit opioid use.
Two studies comparing buprenorphine and methadone found no difference in the frequency of adverse effects,2,3 but one of the two reported an increased level of sedation in the methadone group (58% vs. 26%).3 A third study comparing buprenorphine with placebo reported that adverse effects were similar in the two groups.4
Clinical practice guidelines encourage the use of buprenorphine and methadone as medication-assisted treatments.5,6 Both medications were given a level A rating, indicating that a strong level of evidence was found and that the intervention benefits substantially outweighed harms.6 Factors including availability of methadone facilities, a patient's ability to meet the requirements associated with a treatment program, the safety profiles of buprenorphine and methadone, and patient preference should be considered when helping patients determine which treatment option best fits their needs.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD002207.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
REFERENCESshow all references
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, Va.: American Psychiatric Association; 2013....
2. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60(1):39–50.
3. Petitjean S, Stohler R, Déglon JJ, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001;62(1):97–104.
4. Krook AL, Brørs O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533–542.
5. Handford C, Kahan M, Srivastava A, et al. Buprenorphine/naloxone for opioid dependence: clinical practice guideline. Toronto, Ontario: Centre for Addiction and Mental Health (CAMH); 2011.
6. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical practice guideline: management of substance use disorders (SUD). Washington, DC: Department of Veterans Affairs, Department of Defense; 2009.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2018
Access the latest issue of American Family Physician